These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 31120351)
1. The effect of asparaginase therapy on methotrexate toxicity and efficacy in children with acute lymphoblastic leukemia. Kloos RQH; Pieters R; van den Bos C; van Eijkelenburg NKA; de Jonge R; van der Sluis IM Leuk Lymphoma; 2019 Dec; 60(12):3002-3010. PubMed ID: 31120351 [TBL] [Abstract][Full Text] [Related]
2. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J; J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125 [TBL] [Abstract][Full Text] [Related]
3. Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. Winick NJ; Bowman WP; Kamen BA; Roach ES; Rollins N; Jacaruso D; Buchanan GR J Natl Cancer Inst; 1992 Feb; 84(4):252-6. PubMed ID: 1734087 [TBL] [Abstract][Full Text] [Related]
4. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity. Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948 [TBL] [Abstract][Full Text] [Related]
5. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. Conter V; Aricò M; Valsecchi MG; Rizzari C; Testi AM; Messina C; Mori PG; Miniero R; Colella R; Basso G J Clin Oncol; 1995 Oct; 13(10):2497-502. PubMed ID: 7595699 [TBL] [Abstract][Full Text] [Related]
6. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235 [TBL] [Abstract][Full Text] [Related]
7. Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia. Sari NM; Rakhmilla LE; Bashari MH; Zazuli Z; Suryawan N; Susanah S; Reniarti L; Raspati H; Supriyadi E; Kaspers GJL; Idjradinata P Asian Pac J Cancer Prev; 2021 Jul; 22(7):2025-2031. PubMed ID: 34319023 [TBL] [Abstract][Full Text] [Related]
8. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299 [TBL] [Abstract][Full Text] [Related]
9. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. Tower RL; Jones TL; Camitta BM; Asselin BL; Bell BA; Chauvenet A; Devidas M; Halperin EC; Pullen J; Shuster JJ; Winick N; Kurtzberg J J Pediatr Hematol Oncol; 2014 Jul; 36(5):353-61. PubMed ID: 24608079 [TBL] [Abstract][Full Text] [Related]
10. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia]. Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545 [TBL] [Abstract][Full Text] [Related]
11. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia. Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208 [TBL] [Abstract][Full Text] [Related]
12. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study. Lange BJ; Blatt J; Sather HN; Meadows AT Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385 [TBL] [Abstract][Full Text] [Related]
13. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J; J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Aguayo A; Cortes J; Thomas D; Pierce S; Keating M; Kantarjian H Cancer; 1999 Oct; 86(7):1203-9. PubMed ID: 10506705 [TBL] [Abstract][Full Text] [Related]
15. [Treatment of acute lymphoblastic leukemia in adults as an unsolved problem]. Savchenko VG; Parovichnikova EN; Isaev VG; Kulimova EP; Kucher RA; Sokolov AN; Ustinova EN; Gribanova EO; Khoroshko ND; Pivnik AV; Tikhonova LIu; Sarkisian GP; Domracheva EV; Maslova ER; Konstantinova TS; Rekhtman GB; Lapin VA; Miliutina TI Ter Arkh; 2001; 73(7):6-15. PubMed ID: 11523412 [No Abstract] [Full Text] [Related]
16. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342 [TBL] [Abstract][Full Text] [Related]
17. Methotrexate plus L-asparaginase. An active combination for children with acute nonlymphocytic leukemia. Hudson MM; Dahl GV; Kalwinsky DK; Pui CH Cancer; 1990 Jun; 65(12):2615-8. PubMed ID: 2340462 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy related fatal neurotoxicity during induction in acute lymphoblastic leukemia. Ray M; Marwaha RK; Trehan A Indian J Pediatr; 2002 Feb; 69(2):185-7. PubMed ID: 11929036 [TBL] [Abstract][Full Text] [Related]
20. Solitary serum methotrexate level 36 hours post high-dose methotrexate: A safe, efficacious, and cost-effective strategy to monitor methotrexate toxicities in childhood leukemia in resource-limited centers. Khera S; Kapoor R; Pramanik SK Pediatr Blood Cancer; 2020 Jul; 67(7):e28387. PubMed ID: 32400952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]